News | Artificial Intelligence | November 12, 2024

Provides 22% overall improvement in detecting challenging and aggressive cancer subtypes and enables clinicians to incorporate a prior exam into current screening Analysis


Nov. 12, 2024 — iCAD, Inc., a provider of clinically proven AI-powered cancer detection solutions, recently announced its ProFound Detection Version 4.0 for Digital Breast Tomosynthesis (DBT) has received clearance from the U.S. Food and Drug Administration (FDA). This next-generation AI solution, trained using advanced deep learning convolutional neural networks (CNN), offers advancements in cancer detection and specificity, achieving a 6.3% improved area under the receiver operating characteristic curve (AUC) over prior version, significantly improving the identification of hard-to-find and aggressive cancers while reducing false positives. This version also introduces an option for clinicians to incorporate a prior exam into a current exam’s ProFound Detection analysis.

With today’s FDA clearance, ProFound Detection Version 4.0 is now available for implementation in the U.S. Additional global and vendor-specific regulatory expansions are anticipated through 2025.

Compared to previous version 3, ProFound Detection Version 4.0 provides a 22% overall improvement in detecting some of the most challenging and aggressive cancer subtypes, including:

  • 50% improvement in identifying cancers within dense breast tissue,
  • 60% improvement in identifying invasive lobular cancers,
  • 21% improvement in detecting invasive cancers, and
  • 38% improvement in identifying cancers smaller than 1 cm

“With FDA clearance of ProFound Detection Version 4.0, iCAD continues to set new benchmarks in cancer detection, especially in the most challenging cases where accurate and early detection is critical,” said Dana Brown, President and CEO, iCAD. This "not only enhances detection for cancers feared most by even the expert fellowship-trained breast radiologists, but also reduces the burden of potential false positives, thereby providing clinicians with a highly precise and efficient AI concurrent-reader solution.”

“ProFound Detection Version 4.0 will dramatically improve breast cancer detection,” said Dr. Chirag Parghi, MD, MBA, Chief Medical Officer at Solis Mammography. “The newest version’s ability to detect subtle invasive cancers, especially within dense breast tissue, addresses one of the biggest challenges in breast imaging today. The improved precision in ProFound Detection’s lesion marking combined with the option to incorporate prior exams allows for improved clinical accuracy and more efficient reading workflows.  Collectively, these upgrades will enhance the AI-enriched interpretation experience leading to meaningful adoption of AI."

Along with improved cancer detection capabilities, ProFound Detection Version 4.0 delivers more precise lesion marking, with an 18% improvement in cases with no marks, reducing potential false positives by enhanced specificity performance. This includes:

  • 20% fewer marks related to vascular calcifications, and
  • 51% fewer marks related to non-vascular calcifications.

 ProFound Detection Version 4.0 also enables clinicians to incorporate a prior exam into its AI analysis and case-score/lesion assessment on the current case, emulating the approach radiologists take when interpreting current screening exams with historical context. By integrating prior imaging data, the software provides greater precision and insight, further enhancing clinical decision-making.

iCAD will showcase this next-generation AI at the upcoming 2024 Radiological Society of North America (RSNA) annual meeting in Chicago, Ill.  

Visit iCAD’s RSNA event page to learn more and book a live demonstration: https://www.icadmed.com/about/news-events/upcoming-tradeshows-and-meetings/rsna-2024


Related Content

News | Breast Imaging

Aug. 28, 2024 — Rezolut, LLC recently debuted its latest offering for patients during their annual mammogram ...

Time August 29, 2024
arrow
News | Digital Pathology

Paige has launched OmniScreen, an AI-driven biomarker module capable of evaluating over 505 genes and detecting 1,228 ...

Time August 27, 2024
arrow
News | RSNA

July 31, 2024 — The National Imaging Informatics Course (NIIC), a pioneering program in the radiology field, will return ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Breast Imaging

July 29, 2024 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the ...

Time July 29, 2024
arrow
News | Breast Imaging

July 29, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced a ...

Time July 29, 2024
arrow
Videos | Information Technology

Industry trade shows and conferences seem to be making their comeback in 2024. And the Healthcare Information and ...

Time July 25, 2024
arrow
News | Digital Pathology

July 24, 2024 — Proscia, a developer of artificial intelligence (AI)-enabled digital pathology solutions for precision ...

Time July 24, 2024
arrow
Videos | Breast Imaging

Don't miss ITN's latest "One on One" video interview with AAWR Past President and American College of Radiology (ACR) ...

Time July 24, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
Subscribe Now